Estrella Immunopharma, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Cheng Liu and CFO Peter Xu certified the Q2 2026 10-Q (quarter ended June 30, 2026, filed August 13, 2026) under SOX §302 and §906, attesting that disclosure controls, internal controls over financial reporting, and financial statements fairly present the company's condition. No deficiencies, material weaknesses, or fraud were disclosed.
Why this rating
Routine mandatory SOX certifications. No disclosed control deficiencies or fraud. Standard periodic compliance filing with no operational or financial news.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.